Orphenadrine Citrate
Prescription상품명: ORPHENADRINE CITRATE
About This Medication
DESCRIPTION Orphenadrine citrate is the citrate salt of orphenadrine. It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol. The chemical name of orphenadrine citrate is (±) -N,N -Dimethyl-2-[( o -methyl-α-phenylbenzyl)oxy]ethylamine citrate (1:1) having molecular formula C 18 H 23 NO•C 6 H 8 O 7 and molecular weight of 461.51. It has the following structural formula: Each tablet for oral administration contains 100 mg orphenadrine citrate. Each Orphenadrine citrate extended- release tablet contains the following inactive ingredients: hydroxypropyl methylcellulose, lactose monohydrate and magnesium stearate. Image
유효 성분
| 성분 | 함량 |
|---|---|
| Orphenadrine Citrate | - |
적응증 및 용법
용량 및 투여 방법
Side Effects Overview
경고 및 주의 사항
WARNINGS Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.
금기
CONTRAINDICATIONS Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.
Frequently Asked Questions
INDICATIONS AND USAGE Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.
DOSAGE AND ADMINISTRATION Adults Two tablets per day; one in the morning and one in the evening.
WARNINGS Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.
CONTRAINDICATIONS Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.
Orphenadrine Citrate is a prescription medication. You will need a valid prescription from a licensed healthcare provider.
Similar Tablet Products
Berberisaqui,Betavulgaris,Boldo,Carduusmarianus,Chelidoniummajus,Eleutherococcus Senticosus,Hordeumvulgare,Irisversicolor,Rosmarinusofficinalis,Taraxacumofficinale,Xanthoxylumfraxineum,Ulmusfulva,Glycyrrhizaglabra,Gettysburgaqua,Wildbadaqua,Carlsbadaqua,Atp,Natrummuriaticum,Oxygen,Silicea,Wiesbadenaqua,Hydrogen
Rufinamide
Lisinopril And Hydrochlorothiazide
Spa/Pool Detox
Polyethylene Glycol 3350
Aspirin Low Dose Chewable …
References & Data Sources
- • DailyMed — Orphenadrine Citrate drug label (National Library of Medicine)
- • openFDA — Orphenadrine Citrate label data (U.S. Food & Drug Administration)
- • RxNorm — RXCUI 994521 (NLM Normalized Drug Names)
- • NDC Directory — Orphenadrine Citrate (FDA National Drug Code)
의료 면책 조항
이 페이지의 정보는 교육 목적으로만 제공되며, 전문적인 의학적 조언, 진단 또는 치료를 대체하는 용도로 사용해서는 안 됩니다.
의학적 상태나 의약품에 관한 질문이 있으시면 반드시 의사 또는 자격을 갖춘 의료 전문가에게 조언을 구하시기 바랍니다.
데이터 출처: DailyMed (NLM), openFDA, MFDS